During the first 17 years of life, ACT accounts for approximately 90% of all cancers in R337H carriers, whereas ACT accounts for only 12% of pediatric cancers in TP53 carriers with classic Li-Fraumeni syndrome (LFS) [32]. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.